AngioDynamics, Inc. (NASDAQ:ANGO) Stake Increased by Rothschild Asset Management Inc.
Rothschild Asset Management Inc. boosted its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 0.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 116,912 shares of the medical instruments supplier’s stock after buying an additional 357 shares during the period. Rothschild Asset Management Inc.’s holdings in AngioDynamics were worth $1,895,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of ANGO. Peregrine Capital Management LLC purchased a new position in AngioDynamics during the second quarter valued at approximately $12,133,000. Fenimore Asset Management Inc. purchased a new position in AngioDynamics during the first quarter valued at approximately $9,214,000. Norges Bank purchased a new position in AngioDynamics during the fourth quarter valued at approximately $2,699,000. Bank of Montreal Can boosted its position in AngioDynamics by 126.1% in the second quarter. Bank of Montreal Can now owns 262,846 shares of the medical instruments supplier’s stock valued at $4,261,000 after buying an additional 146,583 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in AngioDynamics by 580.4% in the first quarter. Bank of America Corp DE now owns 166,555 shares of the medical instruments supplier’s stock valued at $2,890,000 after buying an additional 142,076 shares in the last quarter. 85.84% of the stock is currently owned by hedge funds and other institutional investors.
Shares of AngioDynamics, Inc. (NASDAQ:ANGO) opened at 16.46 on Wednesday. The stock has a market cap of $603.32 million, a price-to-earnings ratio of 86.63 and a beta of 1.15. AngioDynamics, Inc. has a 52 week low of $14.80 and a 52 week high of $18.18. The stock’s 50 day moving average is $16.19 and its 200 day moving average is $16.19.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.03. The company had revenue of $86.90 million for the quarter, compared to the consensus estimate of $90.72 million. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The firm’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.19 earnings per share. On average, equities analysts forecast that AngioDynamics, Inc. will post $0.67 EPS for the current year.
ANGO has been the topic of several recent analyst reports. Canaccord Genuity reissued a “hold” rating and set a $16.50 target price on shares of AngioDynamics in a research report on Wednesday, May 31st. Barclays PLC dropped their target price on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 19th. Zacks Investment Research cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a research report on Thursday, July 20th. Cantor Fitzgerald lifted their target price on shares of AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 4th. Finally, BidaskClub cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $18.50.
In related news, CEO James C. Clemmer acquired 5,000 shares of the stock in a transaction that occurred on Friday, July 21st. The shares were bought at an average price of $15.79 per share, for a total transaction of $78,950.00. Following the completion of the transaction, the chief executive officer now directly owns 86,683 shares in the company, valued at $1,368,724.57. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James C. Clemmer acquired 20,000 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were bought at an average price of $15.64 per share, for a total transaction of $312,800.00. Following the transaction, the chief executive officer now owns 86,683 shares of the company’s stock, valued at $1,355,722.12. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 25,316 shares of company stock worth $396,806. 1.88% of the stock is owned by insiders.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.